Takeda, Watson Sue Mylan Over Generic Actoplus Met XR

Law360, New York (January 5, 2012, 3:53 PM EST) -- Takeda Pharmaceutical Co. Ltd. and Watson Pharmaceuticals Inc. sued Mylan Inc. in New York on Tuesday, alleging Mylan infringed several patents when it sought regulatory approval for a generic version of the diabetes treatment Actoplus Met XR.

Osaka, Japan-based Takeda Pharmaceutical and two subsidiaries, as well as Watson-owned Andrx Labs LLC, filed the lawsuit in Manhattan, targeting Mylan and Mylan Pharmaceuticals Inc.

Under the direction its parent company, Mylan Pharmaceuticals lodged an abbreviated new drug application looking for a green light to make, use or sell...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.